NRX Pharmaceuticals, Inc. short interest in 2024
In 2024, NRX Pharmaceuticals, Inc.'s disclosed short interest ran from 3.48% of shares outstanding on 12 Jan 2024 to 5.32% on 31 Dec 2024, a change of +1.84 percentage points. The year's high was 6.27% on 31 Oct 2024 and its low 2.76% on 15 Jul 2024, averaging 4.22% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.15 days on 30 Sep 2024. Full history: NRX Pharmaceuticals, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 3.48% (12 Jan 2024)
- End of year
- 5.32% (31 Dec 2024)
- Change
- +1.84 pp
- High
- 6.27% (31 Oct 2024)
- Low
- 2.76% (15 Jul 2024)
- Average
- 4.22%
- Highest days to cover
- 8.15 (30 Sep 2024)
- SEC filings marked
- 8
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 3.48% | 5.46 | |
| 31 Jan 2024 | 3.42% | 5.59 | |
| 15 Feb 2024 | 4.61% | 4.18 | |
| 29 Feb 2024 | 3.23% | 1.72 | |
| 15 Mar 2024 | 4.43% | 1.00 | |
| 28 Mar 2024 | 4.44% | 3.07 | |
| 15 May 2024 | 4.56% | 1.00 | 10-K filed, results (8-K), 10-Q filed |
| 31 May 2024 | 2.95% | 1.28 | results (8-K) |
| 14 Jun 2024 | 3.34% | 2.64 | |
| 28 Jun 2024 | 2.82% | 3.69 | |
| 15 Jul 2024 | 2.76% | 4.10 | |
| 31 Jul 2024 | 3.14% | 6.73 | |
| 15 Aug 2024 | 4.36% | 6.70 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 4.60% | 5.36 | |
| 13 Sep 2024 | 3.91% | 3.42 | |
| 30 Sep 2024 | 4.88% | 8.15 | |
| 15 Oct 2024 | 5.20% | 6.55 | |
| 31 Oct 2024 | 6.27% | 3.51 | |
| 15 Nov 2024 | 5.52% | 5.90 | 10-Q filed, results (8-K) |
| 29 Nov 2024 | 4.68% | 2.73 | |
| 13 Dec 2024 | 4.96% | 3.19 | |
| 31 Dec 2024 | 5.32% | 1.00 |
See also: NRX Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.